How to take evantumumab

Amivantumab (amivantamab-vmjw) can be used as a first-line treatment option in combination with carboplatin and pemetrexed for adult patients with locally advanced or metastatic non-small cell lung cancer who have an epidermal growth factor receptor (EGFR) exon 20 insertion mutation confirmed by a U.S. Food and Drug Administration (FDA)-approved test. Evantumumab is indicated as monotherapy for adult patients with locally advanced or metastatic NSCLC with an EGFR exon 20 insertion mutation who have previously received platinum-based chemotherapy and have disease progression during or after this period.

1. Preparation before treatment: Doctors will select patients suitable for evantumumab based on the detection results of EGFR exon 20 insertion mutations in tumors or plasma samples. To reduce infusion reactions, patients should be premedicated with antihistamines, antipyretics, and corticosteroids before the first treatment. During subsequent treatment, patients should continue to take antihistamines and fever-reducing medications.

2. Recommended dosage:

(1) Combination medication:

Patients weighing less than 80Kg: Inject 1400mg every week for the first 4 weeks, and 1750mg every 3 weeks starting from the 7th week.

Patients with weight ≥80Kg: 1750mg injected every week for the first 4 weeks, and 2100mg every 3 weeks starting from the 7th week.

(2) Monotherapy:

Patients weighing less than 80Kg: 1050mg injected every week for the first 5 weeks, and 1050mg every 3 weeks starting from the 7th week.

Patients with weight ≥80Kg: 1400mg injected every week for the first 5 weeks, and 1400mg every 3 weeks starting from the 7th week.

3. Dose adjustment: If the patient experiences adverse reactions, the doctor will adjust the drug dosage according to the situation.